OlympiAD: Olaparib versus Chemotherapy in HER2-Negative Metastatic Breast Cancer and a Germline BRCA Mutation

OlympiAD: Olaparib versus Chemotherapy in HER2-Negative Metastatic Breast Cancer and a Germline BRCA Mutation

User Photo
moasc

3 years
3,411 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Rita Mehta, MD of UC Irvine Health gives an overview of the OlympiAD study, which focuses on the use of olaparib in HER2 negative metastatic breast cancer. This was recorded at the 2017 MOASC Spotlight on Clinical Oncology in Huntington Beach, CA. Abstract LBA4: OlympiAD: Olaparib versus Chemotherapy in HER2 Negative Metastatic Breast Cancer and a Germline BRCA Mutation
Up Next Autoplay
User Photo